CAR T-cell Therapy in Patients With Renal Dysfunction

This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.

Trial Details

NCT ID
NCT05909059
Phase
PHASE2
Sponsor
Northside Hospital, Inc.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Fludarabine
  • Cyclophosphamide
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma
  • Adequate bone marrow function to receive lymphodepleting chemotherapy
  • Renal function \</= 60mL/min/1.73m2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →